文献速递核素与放射性配体治疗肿瘤 PET/CT放射性药物与辐射防护

[225Ac]Ac-PSMA I&T治疗mCRPC的1期剂量递增研究:安全性、耐受性与剂量学分析

Phase 1 Dose-Escalation Study of [225Ac]Ac-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer: An Analysis of Safety, Tolerability, and Dosimetry.
PubMed 文献 · J Nucl Med · 2026-07-01

该1期剂量递增研究纳入9例转移性去势抵抗性前列腺癌患者,接受2周期8–12 MBq [225Ac]Ac-PSMA I&T治疗。8例出现不良事件,口干最常见(89%);12 MBq队列出现2例剂量限制性毒性,推荐2期剂量为10 MBq。中位总生存15个月,基于平面图像、血尿分析和[68Ga]Ga-PSMA I&T PET/MRI估算红骨髓、肾脏、唾液腺和肿瘤的中位吸收剂量分别为0.21、1.59、1.43和11.22 Gy/MBq。

要点

  • 推荐2期剂量为10 MBq,12 MBq队列出现2例剂量限制性毒性。
  • 口干最常见(89%),贫血和乏力各占44%。
  • 基于定量SPECT/CT的225Ac剂量学不可行,剂量学限于平面图像及血尿样本。

核心结论

  • 该1期试验推荐[225Ac]Ac-PSMA I&T的2期剂量为10 MBq。
  • 225Ac剂量学受限于全身平面图像及血尿样本,优化225Ac SPECT/CT成像可能使未来剂量学可行。

研究设计与样本

  • 1期剂量递增研究,纳入9例mCRPC患者,接受2周期8–12 MBq [225Ac]Ac-PSMA I&T治疗。
  • 治疗后密切监测不良事件,14周后按RECIST 1.1用[68Ga]Ga-PSMA I&T PET/MRI评估肿瘤反应。
  • 剂量学基于注射后7天内13个时间点血样、24小时内尿样、10天内全身平面图像(含或不含SPECT/CT),用213Bi和221Fr子体计算时间-活性曲线。

主要发现

  • 8/9例患者出现任何级别不良事件,口干最常见(89%),贫血和乏力各44%。
  • 12 MBq队列出现2例剂量限制性毒性。
  • 中位总生存为15个月(95% CI,0.0–32.5个月)。
  • 基于平面图像、血尿分析和[68Ga]Ga-PSMA I&T PET/MRI,红骨髓、肾脏、唾液腺和肿瘤的中位吸收剂量分别为0.21、1.59、1.43和11.22 Gy/MBq。
  • 4/9例(44%)患者PSA下降≥50%;RECIST 1.1评估部分缓解1例、稳定3例、进展3例、不可评估2例。

关键数值与推荐

  • 推荐2期剂量为10 MBq [225Ac]Ac-PSMA I&T。
  • PSA下降≥50%见于4/9例(44%)。
  • RECIST 1.1评估:部分缓解1例、稳定3例、进展3例、不可评估2例。
  • 中位总生存15个月(95% CI,0.0–32.5个月)。

临床怎么用

  • 在mCRPC的[225Ac]Ac-PSMA I&T治疗中,2期推荐剂量为10 MBq。
  • 治疗中需关注口干、贫血和乏力等不良事件。
  • 225Ac剂量学目前可基于全身平面图像及血尿样本进行,定量SPECT/CT尚不可行。

局限性

  • 样本量仅9例。
  • 225Ac基于定量SPECT/CT的剂量学不可行,剂量学限于全身平面图像及血尿样本。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Radiopharmaceutical therapy with 225Ac-labeled prostate-specific membrane antigen (225Ac-PSMA) has shown promising results in patients with metastatic castration-resistant prostate cancer (mCRPC). To date, no phase 1 dose-escalation or comprehensive dosimetry study of [225Ac]Ac-PSMA I&T is available. Here, we present the results of the safety, tolerability, and dosimetry data of [225Ac]Ac-PSMA I&T in a phase 1 trial. Methods: Nine patients with mCRPC were treated with an intended 2 cycles of escalating activity of [225Ac]Ac-PSMA I&T, ranging from 8 to 12 MBq. After treatment with [225Ac]Ac-PSMA I&T, patients were closely monitored for adverse events. Tumor response was evaluated using [68Ga]Ga-PSMA I&T PET/MRI at 14 wk after therapy in accordance with RECIST version 1.1. For dosimetry, blood sampling was performed at 13 time points up to 7 d and urine sampling was conducted up to 24 h postinjection. Time-activity curves were calculated using the radionuclide daughters 213Bi and 221Fr. Whole-body planar images with or without SPECT/CT images were acquired up to 10 d postinjection. Results: Adverse events of any grade were observed in 8 of 9 patients. Xerostomia was most frequently (89%) reported, followed by anemia (44%) and malaise (44%). In the third cohort of patients who were treated with 12 MBq, 2 dose-limiting toxicities were observed, resulting in a recommended phase 2 dose of 10 MBq. The median overall survival was 15 mo (95% CI, 0.0-32.5 mo). The median absorbed doses for red marrow, kidneys, salivary glands, and tumors were 0.21, 1.59, 1.43, and 11.22 Gy/MBq, respectively, on the basis of planar images, blood and urine analysis, and [68Ga]Ga-PSMA I&T PET/MRI. Dosimetry based on quantitative SPECT/CT images was not feasible for 225Ac. A prostate-specific antigen response of 50% or greater was observed in 4 (44%) of 9 patients. Response was classified in accordance with RECIST 1.1, with partial response in 1 patient and stable and progressive disease in 3 patients each; 2 patients were not evaluable. Conclusion: The results of this phase 1 trial indicate a recommended phase 2 dose of 10 MBq of [225Ac]Ac-PSMA I&T. Dosimetry of [225Ac]Ac-PSMA I&T was limited to whole-body planar images and blood and urine samples. However, the optimization of 225Ac SPECT/CT imaging may enable future dosimetry of [225Ac]Ac-PSMA I&T.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Ling SW, Konijnenberg M, Segbers M, et al. Phase 1 Dose-Escalation Study of [225Ac]Ac-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer: An Analysis of Safety, Tolerability, and Dosimetry. J Nucl Med. 2026. PMID: 42020144. doi:10.2967/jnumed.125.271880

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。